Frank S. Hermance
Analyst · Vertical Research
Thank you, Kevin, and good morning, everyone. AMETEK delivered solid earnings in the first quarter, despite a very challenging global macro environment. Overall demand across a number of our markets remains weak. In particular, we’re seeing meaningful headwinds within our oil and gas and metals markets. These headwinds are larger than we anticipated when we started the year. Although these short-term headwinds are challenging, we remain confident in the long-term positioning and growth prospects for our business. Before covering the financial highlights, please note that any references made to 2015 results, will be on an adjusted basis, excluding the realignment costs in 2015. Now onto the financial results. In the first quarter, sales declined 4% to $944.4 million. Organic sales were down 9%, acquisitions added 5%, and foreign currency was a 1% headwind during the quarter. Operating income for the first quarter declined 12% to $208.5 million, and operating income margin in the quarter was 22.1% versus 24.1% in the first quarter of 2015. Net income for the quarter was $134.2 million, and diluted earnings per share of $0.57 were down 10% over last year's first quarter, meeting our Street guidance. Operating cash flow was $152 million in the quarter, up 24% over the prior year. Now turning to the individual operating groups. The electronic instruments group reported a sales decline of 4% to $569 million for the quarter. Organic sales declined 8%. The acquisitions of Surface Vision, Brookfield Engineering and ESP/SurgeX contributed 5%, and foreign currency was a 1% headwind. The lower sales versus prior year were driven largely by our process businesses, which had exposure to oil and gas markets. We’re seeing incremental weakness above our prior expectations in oil and gas, both in the upstream, and in the mid and downstream markets. EIG’s operating income declined 12% to $141.8 million, and operating margins were 24.9% in the quarter versus 27% in last year’s first quarter. The electromechanical group reported overall sales down 4% to $375.4 million. Organic sales were down 9%. The acquisition of Global Tubes added 6%, and foreign currency was a 1% headwind. The lower sales were driven largely by the impact from commodity price deflation in our Engineered Materials Interconnect & Packaging Business, as well as from soft demand in our floor care and specialty motors business. EMG’s operating income of $79.4 million was down 10% from last year's first quarter, and operating margins were 21.2% in the quarter, versus 22.7% in the first quarter of 2015. I’ll now provide some updates on our four growth strategies of operational excellence, global and market expansion, new product development and strategic acquisitions. Each of these strategies plays an integral role in the overall growth and success of AMETEK. We’re focused on consistently executing on each of these strategies over the business cycle. However, in slow growth environments, we increased our focus on strategic acquisitions and operational excellence initiatives, while ensuring, we continue to make targeted investments in research and development and global expansion. First, let me touch on acquisitions. We’ve had a good start to the year, acquiring two businesses in the first quarter, Brookfield Engineering Laboratories and ESP/SurgeX. Combined, we deployed approximately $300 million in capital and acquired nearly $100 million in sales. ESP/SurgeX is a leader in power protection. Their patent protected products operate at the plug level, and monitor, protect, analyze, and diagnose power-related issues remotely or on-site. In addition, their products help control power to mission critical equipment. ESP is a great strategic fit with our existing power protection platform. It is highly complementary with our recently acquired Powervar business, providing us with new opportunities for product innovation and market expansion. The company has annual sales of approximately $40 million and is headquartered in North Carolina. Brookfield is the global leader in viscosity measurement instrumentation for quality control applications. The company provides a complete range of viscometers and rheometers, as well as instrumentation for the analysis of texture and powder flow. Key applications for Brookfield’s products include research, development, and production of food and beverage, pharmaceutical, paint, and petroleum products. The addition of Brookfield allows AMETEK to expand our laboratory instrumentation platform into a broader range of adjacent markets and applications. They’re headquartered in Middleboro, Massachusetts with additional operations in Germany, the United Kingdom, China, and India and have annual sales of approximately $55 million. The integration of both of these acquisitions is going very well. As part of our acquisition integration process, we conduct monthly integration meetings with each acquired company for at least the first six months following acquisition. These meetings are important drivers of the success of our acquisition strategy, as they allow us to closely monitor progress on key integration activities and value drivers during the critical early stages of the integration. Acquisitions will continue to be a key focus for us. They will continue to be the primary use of our strong cash flow and financing facilities. Our acquisition and business teams remain very active, and so we’re quite bullish on our opportunity to continue to deploy capital and create meaningful shareholder value. Now turning to operational excellence, our management teams and employees are doing a great job, driving continued operational efficiencies and improvements through their businesses by leveraging our operational excellence tools. Our operational excellence initiatives take on even greater importance, and become more of a focus in slow growth environments. For all of 2016, we now anticipate approximately $130 million of total operational excellence savings, with our global sourcing and strategic procurement initiatives driving approximately $60 million of the total savings. The total operational excellence savings is up from our initial estimate of $120 million, as a result of the continued strong efforts of our teams. Now moving on to new products. We are pleased with the continuous success of our new product development activities. Our businesses are doing an outstanding job developing and introducing exciting new products. These new product developments are targeted at both expanding in existing markets, and penetrating adjacent markets. Despite the slow growth environment, we continue to invest meaningfully in our new product development activities. In 2016, we expect to spend approximately $210 million on RD&E, up 5% from last year. We continue to see excellent results from this investment, as our vitality index which measures revenue from products introduced over the last three years, was 22% of sales in the quarter. We have a number of notable new product introductions within the quarter. The new Xepos energy dispersive X-ray fluorescence spectrometer from our SPECTRO Analytical Instruments business is considered a breakthrough product for performing elemental analysis. The compact bench-top unit incorporates a number of advances, that allow it to perform rapid multi-element analysis with greater accuracy and precision. The instrument's enhancements make it suitable for demanding environmental and geological research, as well as precise at line quality control in chemical and petrochemical production, food processing, and pharmaceutical production. The new Extreme Performance Series of MIL-XTM fans from AMETEK Rotron delivers best-in-class airflow for harsh and demanding military, aerospace, and industrial environments. The new fans feature shock proof Mil spec construction, and are optimized for electronic cooling applications. The fans are offered with a range of features that permit their use in a variety of situations and configurations. They can be used alone, or stacked with multiple fans to cool electronics, equipment racks, and personnel in airborne, land-based, and sea-borne installations. Our Zygo business provided high precision optics that were used in the recent detection of gravitational waves that confirmed one of the key predictions in Einstein’s 1915 general theory of relativity. The international team of scientists that collaborated on the discovery relied on advanced LIGO detectors that incorporated very high precision optical components manufactured by Zygo. The optics manufactured to some sub nanometer tolerances are among the most precise optics ever made. I’d like to recognize the Zygo team on their contribution to the success of this important global scientific project. Now turning to global and market expansion. Global and market expansion continues to be an important part of our long-term growth. In the first quarter, international sales represented 53% of our total sales. We remain committed to expanding our presence in attractive higher growth regions and market segments through continued investments in our sales and service capabilities, and through the expansion of our technology into new adjacent market segments. I want to highlight one of the recent success of our adjacent market expansion initiatives. Our process instruments business has pioneered near infrared tunable diode laser absorption spectroscopy, or TDLAS technology. This technology has been very successful for use in online process applications within natural gas processing and petrochemical production. The process instruments business is now adapting to TDLAS technology for use in online pharmaceutical processing, through modifying its existing Model 5100 Series analyzers to provide continuous process control of pharmaceutical drying. The use of this technology as an online analysis tool, allows manufacturers to obtain a clearer picture of the drying process in real time. It is an economical and efficient technique for determining dryer endpoint detection, since it eliminates the need for pharmaceutical manufacturers to stop, analyze, and restart the drying process. The process instruments team is starting to see strong interest in this new market application for an existing technology. Now turning to the outlook for 2016. As a result of the end market challenges, we now anticipate overall sales for 2016 to be roughly flat versus 2015, with organic sales down low to mid single-digits on a percentage basis versus 2015. We expect earnings for 2016 to be in the range of $2.42 to $2.52 per diluted share, down 1% to 5% over last year. Our overall second quarter 2016 sales are expected to be down low single digits, versus the second quarter of 2015. We estimate our second quarter earnings to be approximately $0.58 to $0.59 per diluted share, down 8% to 9% over last year's second quarter. In summary, while the economic environment across many of our markets remains challenging and very difficult to predict, we remain focused on executing on the factors within our control. This includes deploying capital on strategic acquisitions, making growth investments in new product development and global expansion, and executing on our operational excellence initiatives. Our strong cash flow and prudent operating model give us confidence that we will continue our long track record of strong performance and shareholder value creation. Bob will now cover some of the financial details, and then we will be glad to take your questions.